Professional Documents
Culture Documents
Low infant birth weight can be associated with immediate, as well as long-term,
effects for the infant that will carry on, and most likely worsen, with adulthood. Both the
thrifty phenotype and the fetal origins hypotheses connect low birth weight to insulin
resistance, type 2 diabetes, hypertension, obesity, and other metabolic complications (1,
2). Infants are characterized as being of low birth weight if they are born weighing less
than five pounds and eight ounces (3), and this cutoff is also used to identify intrauterine
growth restriction(IUGR) in babies born at term (4). Infants born at a low birth weight,
and therefore likely IUGR, almost certainly have experienced some sort of growth or
these deficiencies. The discussion lies within the effects, both long-term and immediate,
on metabolic diseases or their precursors in infants of low birth weight. Considering that
diabetes and obesity are national concerns, studies regarding the possible causes of, or at
least predispositions to, these diseases may offer insight to their prevention or to
A study examined twenty-five year old subjects who were either born appropriate
for gestational age or IUGR-born to evaluate decreased insulin sensitivity (5). In the
study’s subjects, “body fat was significantly higher in the IUGR group,” even though
both groups had comparable body mass indexes, and the results revealed decreased
insulin sensitivity in IUGR subjects(5). As with the former test, glucose concentration in
the blood is tested to determine insulin resistance and will be seen in higher
adults, other studies observed insulin resistance in mid and late childhood (6), while still
another cited incidence of insulin sensitivity reduction as early as age one in infants born
at a low birth weight (7). Insulin plays an important role in the body’s metabolic
threatening (1,7). So what factors associated with low birth weight would cause insulin
resistance?
After being born at a low birth weight, most children experience a catch-up
growth period that occurs largely between birth and age two, and it is this speedy weight
gain period that is often associated with the insulin resistance and related complications
(7). In a study of low birth weight infants of age one, a marked reduction in insulin
sensitivity was already observed (8). These findings suggest that the catch-up growth
period after birth is a crucial time period in the infant’s development of insulin resistance
and future complications. After the catch up period between birth and two years, a group
of infants were studied and compared during ages two to four years: “the gains in
abdominal fat and body adiposity were strikingly higher in small for gestational
age(SGA) than appropriate for gestational age children(AGA)” (7). Also in this study, the
already increased insulin resistance in SGA infants showed a further increase in the next
years, contrasting the lack of change in the AGA infants (7). The disturbing observation
here is that despite the fact the SGA infants had already experienced their catch-up
growth period, they still continued to add extra fat tissue while their insulin sensitivity
further reduced. Perhaps the early relation of insulin resistance and fat gains continues to
were studied (6) and may help provide a link between the early insulin resistance and
adult metabolic diseases. In this study, a significant difference was seen between children
born SGA versus those born AGA: SGA children had higher fasting glucose, insulin
levels, and insulin resistance. In addition, “the greatest insulin resistance was observed in
those with low birth weight and high current weight” (6). To relate a previous study, a
birth and age two and the increased insulin levels and weight gain. So, at this stage,
with age, despite catch-up growth. These findings would then advance into young
adulthood where, as earlier mentioned, insulin resistance and body fat are still
that relates hypertension, obesity, and type 2 diabetes; one researcher “was able to
demonstrate that the smaller the birth weight or the weight at one year, the greater was
the prevalence of this syndrome X in adult life (9). An additional study was able to
quantify the risk: “the odds increased 1.72 times for each tertile decrease in birth weight”
(10). Additionally, a study was conducted to research the factors involved in the
development of the metabolic syndrome, specifically low birth weight and current
overweight status (1). Here researchers discovered that birth weight was markedly lower
in the group of children with metabolic syndrome, while the ratio of current weight
compared with birth weight was high. “These findings indicate that in individuals with a
similar level of obesity, subjects with a lower birth weight and subsequent greater weight
At increasingly smaller birth weights, the infant requires an even quicker rate of
catch up growth to reach the appropriate size by approximately age two, and therefore an
even greater alteration to the infant’s metabolic processes. A study using pre-term infants
attempted to evaluate whether the insulin resistance was actually due to the SGA/AGA
status, or the need for catch up growth after birth (11). The study of the very low birth
weight preterm infants concluded “the adverse metabolic pattern of pre-school VLBW
children seems related to post-natal events (rapid weight growth) independently of their
being born small- or appropriate-for gestational age” (11). This study still supports the
evidence that low birth weight is a definite risk factor for insulin resistance, and also adds
that an even greater risk may be connected to those low birth weight infants who
However, catch-up growth is ultimately the result of either low birth weight or
IUGR. This restriction has proved to have a substantial effect on insulin sensitivity (12);
but is the effect due to catch-up growth or to other factors of incomplete development in
the fetus? In a study of ninety children with nonalcoholic fatty liver disease (NAFLD), “a
highly prevalent and potentially progressive condition in adults, now considered the
hepatic [liver] expression of the metabolic syndrome,” 39.9% of the children were born
SGA, which was about four times greater than the general pediatric population of the
hospital (12). This study shows that the liver disease is more prevalent in SGA children
and says that the related insulin resistance will begin to appear even during the catch up
did not, a difference in insulin sensitivity was not found. This particular study then
concluded that childhood catch up growth was not the risk factor for future onset of type
2 diabetes (13), which somewhat contradicts the findings of the more current study
involving pre-term infants and even more recent studies using catch up growth between
zero and twenty-four months as an indicator (11). Most likely, the catch up growth is best
which case, the catch up growth does not necessarily lead to diabetes or obesity, but
So then, the studies would indicate that events leading up to birth are responsible
for the negative chain of events that occurs after birth. Fetal development is a very
especially when the nutrient supply to the fetus is compromised. The limited supply will
cause the fetus to adapt structurally and functionally in order to survive through a process
called “programming” (1). During this critical stage of development, the fetus makes
these changes to itself for survival, but the programming “also results in permanent
damage to the metabolic status of the fetus” (1). Essentially, in the programming
adjustment, an immediate need is met and therefore proves the programming beneficial at
that time. However, remaining in this “adjusted” state will be detrimental to the infant
once the proper or sufficient nutrients are present. The unfavorable conditions may cause
adjustment by affecting growth and proper use of pancreatic beta-cells, which are related
to insulin secretion, and, when coupled with insulin resistance, provide the defects
leading to type 2 diabetes later in life (11,13). However, specifically targeting beta-cells
as a primary defect is difficult, and better is the conclusion that beta-cell deterioration in
combination with increasing insulin resistance can be a cause of later type 2 diabetes
(13). Fetal malnutrition and subsequent programming are can also be contributors to the
artery-related problems hypertension and high blood pressure and additionally may
predispose the fetus to the development of insulin resistance by regulating the types of
muscle fibers formed (1). Linking the beta-cell defects with those of the muscle type may
further peripheral and central fat deposition (7). This would explain the significantly
higher gains in abdominal and total body fat in SGA infants compared with AGA infants
during the growth period of two to four years of age (7). The gains between the two
groups in this study were actually similar in weight, height, and BMI with prominent
The fetal environment and infant are then predisposed to, or at-risk of, developing
metabolic diseases, but what, beyond childhood, are the outcomes of low birth weight? In
a study of Chinese adults, obesity, hypertension, type 2 diabetes, and birth weight were
all examined and associations between birth weight and other data were assessed (2).
Birth weight proved to be a predictor for future complications, especially low birth
weight: low birth weights showed the highest incidences of type 2 diabetes and
abdominal obesity, while the effects of birth weight combined with abdominal obesity
showed a significant increase in the prevalence of type 2 diabetes (2). These findings
indicate that low birth weight is an independent risk factor for both type 2 diabetes and
abdominal obesity. Considering that low birth weight is a risk factor for both insulin
resistance and obesity and that obesity itself is related to insulin resistance, taking
specific measures to reduce obesity would be almost imperative for persons born at a low
babies born at a low birth weight, or SGA (7, 9). “Approximately ten percent of children
born SGA fail catch-up growth and remain short” (14). Growth hormone treatment has
been approved and is now a treatment for patients born short and SGA (14), but certain
risk factors do raise concern: growth hormone has previously been linked to increased
insulin levels and insulin resistance (14). Since SGA infants are already considered to be
growth hormone (GH) on treated SGA patients. One study compared GH treated short
SGA children with non GH treated children to evaluate this concern and found that while
insulin resistance was increased during GH treatment, baseline was recovered after
discontinuation (14). In fact, the treated short SGA children actually experienced positive
effects on blood pressure and cholesterol levels that the untreated children did not and
were also taller, as a result of the GH treatment (14). GH has also shown a rise in BMI
due to a rise in lean body mass, which is useful in comparing the two groups: the groups
had comparable BMI’s, but the treated were taller, possibly indicating that the untreated
have more fat mass, though this idea needs further research (14). Metformin has also
been used in treatment with low-birth-weight insulin resistant children to increase insulin
sensitivity, but has shown also to reduce total and abdominal fat while helping to increase
Programming helps the fetus to adapt to its circumstances (1). A malnourished fetus will
mostly likely experience IUGR and be born at a low birth weight (4). In order to make up
for the inadequacy, most SGA children will experience “catch-up” growth between birth
and two years of age (7). This “resets the hypothalamus-pituitary axis, leading to an
increase in growth factors,” and the possible, likely development of hypertension and
insulin resistance (1). Insulin resistance is then linked to many other complications
including obesity, type 2 diabetes, and the metabolic syndrome (2, 9). In conclusion,
prevention of metabolic diseases begins in the fetal environment. If born at a low birth
weight, an infant can be considered at a higher risk for insulin resistance, diabetes,
obesity, hypertension, and the metabolic syndrome. If the infant experiences a rapid
catch-up growth that progresses into overcompensation, then that infant is most likely at a
greater risk for such problems. Knowing the relationship between low birth weight and
metabolic diseases is helpful in developing preventative methods for and decreasing the
1. Abe Y, Kikucki T, Nagasaki K, Hiura M, Tanaka Y, Ogawa Y, Uchiyama M. Lower birth weight
associated with current overweight status is related with the metabolic syndrome in obese
Japanese children. Hypertens Res. 2007 Jul;30(7):627-34. PMID:17785931 [PubMed – indexed
for MEDLINE] Accessed February 15, 2008.
2. Tian JY, Cheng Q, Song XM, Li G, Jiang GX, Gu YY, Luo M. Birth weight and risk of type 2
diabetes, abdominal obesity and hypertension among Chinese adults. Eur J Endocrinol. 2006
Oct;155(4):601-7. PMID: 16990660 [PubMed – indexed for MEDLINE] Accessed February 15,
2008.
3. Iyasu S, Tomashek K, Barfield. Infant mortality and low birth weight among black and white
infants – United States, 1980-2000. MMWR Weekly. 2002 Jul 12;51(27):589-92. Available at
www.cdc.gov. Accessed March 2, 2008.
4. Peleg D, Kennedy CM, Hunter SK. Intrauterine growth restriction: identification and
management. Am Fam Physician. 1998 Aug;58(2): 453-60, 466-7. PMID:9713399 [PubMed –
indexed for MEDLINE] Accessed February 15, 2008.
5. Jaquet D, Gaboriau A, Czernichow P, Levy-Marchal C. Insulin resistance early in adulthood born
with intrauterine growth retardation. J Clin Endocrinol Metab. 2000 April; 85(4):1401-6. PMID:
10770173 [PubMed – indexed for MEDLINE] Accessed February 15, 2008.
6. Gupta M, Gupta R, Pareek A, Bhatia R, Kaul V. Low birth weight and insulin resistance in mid
and late childhood. Indian Pediatr. 2007 Mar;44(3):177-84. PMID: 17413193 [PubMed – indexed
for MEDLINE] Accessed February 15, 2008.
7. Ibanez L, Ong K, Dunger DB, de Zegher F. Early development of adiposity and insulin resistance
after catch-up weight gain in small-for-gestational-age children. J Clin Endocrinol Metab. 2006
Jun;91(6):2153-8. Epub 2006 Mar 14. PMID:16537681 [PubMed – indexed for MEDLINE]
Accessed February 15, 2008.
8. Soto N, Bazaes RA, Pena V, Salazar T, Avila A, Iniguez G, Ong KK, Dunger DB, Mericq MV.
Insulin sensitivity and secretion are related to catch-up growth in small-for-gestational-age infants
at age 1 year: results from a prospective cohort. J Clin Endocrinol Metab. 2003 Aug;88(8):3645-
50. PMID: 12915649 [PubMed - indexed for MEDLINE] Accessed February 15, 2008.
9. Chatelain P. Children born with intra-uterine growth retardation (IUGR) or small for gestational
age (SGA): long term growth and metabolic consequences. Endocr Regul. 2000 Mar;34(1):33-6.
Review. PMID: 10808251 [PubMed - indexed for MEDLINE] Accessed February 15, 2008.
10. Valdez R, Athens MA, Thompson GH, Bradshaw BS, Stern MP. Birthweight and adult health
outcomes in a biethnic population in the USA. Diabetologia 1994 Jun; 37(6):624-31. PMID:
7926349 [PubMed - indexed for MEDLINE] Accessed February 20, 2008.
11. Bo S, Bertino E, Bagna R, Trapani A, Gambino R, Martano C, Mombro’ M, Pagano G. Insulin
resistance in pre-school very-low-birth weight pre-term children. Diabetes Metab. 2006
Apr;32(2):151-8. PMID: 16735964 [PubMed – indexed for MEDLINE] Accessed February 15,
2008.
12. Nobili V, Marcellini M, Marchesini G, Vanni E, Manco M, Villani A, Bugianesi E. Intrauterine
growth retardation, insulin resistance, and nonalcoholic fatty liver disease in children. Diabetes
Care. 2007 Mar;44(3):177-84. PMID 17413193 [PubMed - indexed for MEDLINE] Accessed
February 15, 2008.
13. Veening MA, van Weissenbruch MM, Heine RJ, Delemarre-van de Waal HA. Beta-cell capacity
and insulin sensitivity in prepubertal children born small for gestational age: influence of body
size during childhood. Diabetes. 2003 Jul;52(7):1756-60. PMID: 12829643 [PubMed – indexed
for MEDLINE] Accessed February 20, 2008.
14. van Dijk M, Bannink EM, van Pareren YK, Mulder PG, Hokken-Koelega AC. Risk factors for
diabetes mellitus type 2 and metabolic syndrome are comparable for previously growth hormone-
treated you adults born small for gestational age (sga) and untreated short SGA controls. J Clin
Endocrinol Metab. 2007 Jan;92(1):160-5. Epub 2006 Oct 24. PMID: 17062774 [PubMed –
indexed for MEDLINE] Accessed February 23, 2008.